NAS10028,142+0.54%S&P7,563+0.29%GOLD$3,929−1.02%BTC$77,513+1.09%VIX20.95−0.95%latest tape · as of 20:14 UTC · 3 Nov
The Screen · Financials · Financial Data & Stock Exchanges
Cboe Global Markets
CBOE · a US exchange · USD · Market cap $35.0B · 1,661 employees
Cboe Global Markets, Inc., through its subsidiaries, operates as a derivatives and securities exchange network that delivers cutting-edge trading, clearing, and investment solutions in the United States and internationally.
FAIL · Does not pass the screen
349.22 USD
Price as of 2 Nov 2026Daily close, not a live quote
Screened 2026-11-02 · the tape above runs as of 20:14 UTC · 3 Nov · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price349.22 USD at the 2 Nov 2026 close
Our value readOvervalued vs our fair value, as of 2 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.69, read 2026-11-02
Ethical does not pass the values gate
Price349.22 USD
Fair value273.66
Ethical score10.0/100
Value readOvervaluedas of 2 Nov 2026
Our investment reviews on this name
2026-10-11Read Markup253.26+37.9% to today ✓Distribution gives way to Markup first Markup read since August
2026-10-02Read Distribution253.26+37.9% to today Markup gives way to Distribution after a 10% slide in 13 weeks
2026-07-02Read Markup281.91+23.9% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Cboe Global Markets holds its Markup at $349.22. The statistical read favours the sellers, held for 56 days.
As held on the ledger · 2026-11-02
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 56 days
Price at the screen
$349.22
Valuation
26.15 trailing · 22.14 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.41
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Business activity: Financials sector
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Cboe Global Markets does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-02. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CBOE's ethical verdict changes
Today CBOE does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 2 Nov 2026: it trades above our $273.66 fair value estimate, strong competitive moat, 22.90% revenue growth.
Fair value range in USD, drawn from the 2026-11-02 screen. The gold marker is the market price at the same screen. The price runs 27.6% above the base estimate.
Where our models see it going: fair-value estimate $273.66, with a range of $269.10 to $314.70, dated to the 2026-11-02 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 22.1x forward earnings, the price already runs ahead of the business. It trades 23% above our $273.66 fair value, so you would be buying at a premium, not a discount. The strong moat is real, but quality alone does not make an expensive price cheap.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CBOE trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-30Markup$320.42+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (14 analysts) rates it hold, with a mean price target of $330. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$320.42+4.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (14 analysts) rates it hold, with a mean price target of $330. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup$308.09+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (14 analysts) rates it hold, with a mean price target of $330. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markup$308.09+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (14 analysts) rates it hold, with a mean price target of $330. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markup$308.09+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (14 analysts) rates it hold, with a mean price target of $330. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup$308.09+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (14 analysts) rates it hold, with a mean price target of $330. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markup$308.09+0.0%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (14 analysts) rates it hold, with a mean price target of $330. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markup$308.09+0.0%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (14 analysts) rates it hold, with a mean price target of $330. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markup$308.09+21.6%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 21.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 31% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (14 analysts) rates it hold, with a mean price target of $330.
2026-10-11Markup · changed$253.26+0.0%Entry 7
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 31% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (14 analysts) rates it hold, with a mean price target of $330.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
